Recurrent Prostate Carcinoma Presenting as Omental Large Cell Carcinoma With Neuroendocrine Differentiation and Resulting in Bowel Obstruction

2000 ◽  
Vol 124 (7) ◽  
pp. 1074-1076
Author(s):  
San San Wynn ◽  
Satyagnani Nagabundi ◽  
Jaik Koo ◽  
Nena W. Chin
Keyword(s):  
Cell Carcinoma ◽  
Prostate Specific Antigen ◽  
Small Cell Carcinoma ◽  
Bowel Obstruction ◽  
Metastatic Disease ◽  
Specific Antigen ◽  
Neuroendocrine Differentiation ◽  
Large Cell ◽  
Small Cell ◽  
Antigen Level

Abstract Neuroendocrine differentiation in the neoplastic prostate varies from foci of adenocarcinoma showing immunoreactivity to the pure small cell carcinoma, which correlates with poor prognosis. Widely metastatic disease in unusual sites is reported for small cell carcinoma, and rarely is the serum prostate-specific antigen level elevated. We report a case of recurrent prostate adenocarcinoma presenting as bowel obstruction due to widespread metastatic disease in the omentum and peritoneum. The histopathology of the omental metastasis was that of a large cell neuroendocrine carcinoma, without evidence of an adenocarcinoma. The absence of a clinically evident second primary tumor, the concomitant elevated serum prostate-specific antigen level, and the positive tissue immunoreactivities to prostatic markers all supported the prostatic origin of the omental tumor. Review of the importance of prostatic neuroendocrine differentiation and its unusual metastatic patterns is presented.

scholarly journals Small cell carcinoma of the prostate after low-dose-rate brachytherapy: a case report

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Eva Van Bos ◽  
Peter Dekuyper ◽  
Charlotte Gabriel ◽  
Marjan Waterloos ◽  
Anthony Van Baelen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Dose Rate ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Low Dose ◽  
Specific Antigen ◽  
Small Cell ◽  
Carcinoma Of The Prostate ◽  
Low Dose Rate ◽  
Low Dose Rate Brachytherapy

Abstract Background Small cell carcinoma of the prostate is a rare condition with important differences from prostatic adenocarcinoma in terms of clinical and prognostic characteristics. A low prostate-specific antigen and a symptomatic patient, including paraneoplastic symptoms, characterize small cell carcinoma of the prostate. Diagnosis is made on the basis of prostate biopsy, and fluorodeoxyglucose positron emission tomography/computed tomography is often used for staging because up to 60% of patients present with de novo metastatic disease. Patients with metastatic disease are usually treated with platinum-based cytotoxic chemotherapy regimens similar to those used for small cell carcinoma of the lung. However, prognosis remains poor, with a median overall survival of 9 to 17 months despite therapy. Case presentation This report describes a case of an 80-year-old Caucasian patient with lymph node and bone metastatic small cell carcinoma of the prostate following low-dose-rate brachytherapy for a low-risk prostate carcinoma and treated with chemotherapy and immunotherapy. Conclusion Low-dose-rate brachytherapy might be an etiology of small cell prostate cancer.

scholarly journals Brain Metastasis from Prostate Small Cell Carcinoma: Not to be Neglected

2002 ◽  
Vol 29 (4) ◽  
pp. 375-377 ◽  
Author(s):  
Corrie E. Erasmus ◽  
Wim I.M. Verhagen ◽  
Carla A.P. Wauters ◽  
Erik J. van Lindert
Keyword(s):  
Brain Metastases ◽  
Cell Carcinoma ◽  
Prostate Specific Antigen ◽  
Small Cell Carcinoma ◽  
Prostatic Carcinoma ◽  
Right Hemisphere ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Small Cell ◽  
The Brain

ABSTRACTBackground:Symptomatic brain metastases from prostatic carcinoma are rare (0.05% to 0.5%).Case report:A 70-year-old man presented with a homonymous hemianopsia due to brain metastatic prostatic carcinoma shortly before becoming symptomatic of prostatic disease. CT and MRI of the brain showed a tumour deep in the right hemisphere near the thalamus and involving the optic radiation.Results:Routine haematological and biochemical tests were normal. The prostate specific antigen level was low on two separate occasions. The prostatic and brain tumours showed identical appearances, namely of a poorly differentiated adenocarcinoma with neuroendocrine differentiation (small cell carcinoma).Conclusion:A literature review suggests that small cell carcinoma of the prostate is more likely to spread to the brain compared to adenocarcinoma and that brain metastases indicate a poor prognosis. The prostate gland should be remembered as a possible cause of brain metastases and that a normal serum prostate specific antigen does not exclude this diagnosis.

scholarly journals Adenocarcinoma of the prostate with small cell component and low levels of prostate specific antigen

2020 ◽  
Vol 77 (10) ◽  
pp. 1101-1103
Author(s):  
Sasa Vojinov ◽  
Mladen Popov ◽  
Ivan Levakov ◽  
Aleksandra Levakov-Fejsa ◽  
Dimitrije Jeremic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Carcinoma ◽  
Prostate Specific Antigen ◽  
Small Cell Carcinoma ◽  
Specific Antigen ◽  
Small Cell ◽  
Histopathological Analysis ◽  
Poorly Differentiated Adenocarcinoma ◽  
Adenocarcinoma Of The Prostate ◽  
Poorly Differentiated

Introduction. Prostate cancer is one of the most common malignancies in men. The most common type is acinar adenocarcinoma. Small cell prostate cancer (SCPC) usually occurs together with coexisting prostate adenocarcinoma. Case report. A 72-years-old patient with voiding simptoms is presented. Initial level of prostate specific antigen (PSA) was 2.87 ng/mL. Twelve prostate biopsies were taken and in six of them neoplastic tissue was detected. The viewed tissue was most convenient to ?small cell carcinoma?. Bone scintigraphy did not demonstrate dissemination of the cancer into the skeletal system. Multislice computed tomography (MSCT) of the pelvis did not reveal any special pathological changes. The patient underwent surgery ? radical retropubical prostatectomy. Histopathological analysis revealed a poorly differentiated adenocarcinoma of the prostate with small cell carcinoma zones [Gleason score 5+5 (10), grade III, pT3bN1, stage IV]. Conclusion. Poorly differentiated adenocarcinoma of the prostate, especially in combination with SCPC, is an aggressive malignancy with most cases presenting with the extensive disease dissemination on diagnosis and poor prognosis. Small cell carcinomas of the prostate are extremely rare tumors of the neuroendocrine origin. Patients with mixed prostate cancer, compared to pure SCPC, have a better prognosis and greater survival rate. There is a lack of the evidence guiding treatment for SCPC.

Long-Term Outcomes of Organ Preservation in Patients with Small Cell Carcinoma of the Bladder

2015 ◽  
Vol 94 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Jairam R. Eswara ◽  
Niall M. Heney ◽  
Chin-Lee Wu ◽  
W. Scott McDougal
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Advanced Disease ◽  
Chemical Exposure ◽  
Small Cell ◽  
Cancer Specific Survival ◽  
Entire Cohort ◽  
Aggressive Disease ◽  
Carcinoma Of The Bladder

Background: Small cell carcinoma of the bladder is an uncommon but clinically aggressive disease. There is no standard surgical or medical management for the disease. Methods: Between 1995 and 2009, 28 patients underwent transurethral resection (TUR) and/or cystectomy, chemotherapy, and/or radiation for small cell carcinoma of the bladder at our institution. Results: The median follow-up for survivors was 34 months. Patients presented most often with muscle-invasive disease (T2-4 - 89%), and 21% had lymph node/distant metastases. Tobacco use and chemical exposure were noted in 64 and 4% of patients, respectively. Patients with T1-2N0M0 had a median survival of 22 months compared to 8 months for those with more advanced disease (p = 0.03). Patients with T3-4 or nodal/metastatic disease who were given chemotherapy had an improved survival compared to those with T3-4 or nodal/metastatic disease who did not undergo chemotherapy (13 vs. 4 months, p = 0.005). The median time to recurrence of the entire cohort was 8 months, overall and cancer-specific survival was 14 months, and 5-year survival was 11%. Conclusions: Small cell carcinoma of the bladder is an aggressive disease with poor outcomes. Patients with T1-2N0M0 disease survived longer than those with advanced disease. Patients with T3-4 or nodal/metastatic disease had improved survival with chemotherapy.

Large-cell variant of small cell carcinoma of the ovary with hypercalcaemia

2000 ◽  
Vol 264 (3) ◽  
pp. 157-158 ◽  
Author(s):  
G. Di Vagno ◽  
G. A. Melilli ◽  
G. Cormio ◽  
D. Piscitelli ◽  
A. Ciampolillo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
Cell Variant ◽  
Carcinoma Of The Ovary
Sign in / Sign up

Export Citation Format

Share Document